The estimated Net Worth of Corp /Mn/ Techne is at least $324 Million dollars as of 13 February 2012. Corp Techne owns over 500,000 units of ChemoCentryx Inc stock worth over $324,160,561 and over the last 13 years Corp sold CCXI stock worth over $0.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Corp Techne CCXI stock SEC Form 4 insiders trading
Corp has made over 1 trades of the ChemoCentryx Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Corp bought 500,000 units of CCXI stock worth $5,000,000 on 13 February 2012.
The largest trade Corp's ever made was buying 500,000 units of ChemoCentryx Inc stock on 13 February 2012 worth over $5,000,000. On average, Corp trades about 500,000 units every 0 days since 2012. As of 13 February 2012 Corp still owns at least 6,235,056 units of ChemoCentryx Inc stock.
You can see the complete history of Corp Techne stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Corp Techne's mailing address?
Corp's mailing address filed with the SEC is 614, Northeast McKinley Place, Minneapolis, Hennepin County, Minnesota, 55413, United States.
Insiders trading at ChemoCentryx Inc
Over the last 13 years, insiders at ChemoCentryx Inc have traded over $355,980,520 worth of ChemoCentryx Inc stock and bought 3,166,975 units worth $19,475,662 . The most active insiders traders include Plc Gsk, Rishi Gupta, and (International) Ltd Vifor P.... On average, ChemoCentryx Inc executives and independent directors trade stock every 12 days with the average trade being worth of $4,175,785. The most recent stock trade was executed by Susan M Kanaya on 16 August 2022, trading 19,898 units of CCXI stock currently worth $216,092.
What does ChemoCentryx Inc do?
ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. ChemoCentryx's lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration. Avacopan is also in late stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). ChemoCentryx also has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.
What does ChemoCentryx Inc's logo look like?
Complete history of Corp Techne stock trades at ChemoCentryx Inc
ChemoCentryx Inc executives and stock owners
ChemoCentryx Inc executives and other stock owners filed with the SEC include:
-
Thomas Schall,
Chairman of the Board, President, Chief Executive Officer -
Susan Kanaya,
Chief Financial Officer, Executive Vice President, Chief Administrative Officer, Secretary -
Markus Cappel,
Chief Business Officer, Treasurer -
Dr. Thomas J. Schall Ph.D.,
Founder, Pres, CEO & Chairman -
Susan M. Kanaya,
Exec. VP, Chief Financial & Admin. Officer, Sec. and Director -
Dr. Markus J. Cappel Ph.D.,
Sr. VP, Chief Bus. Officer & Treasurer -
Rita Jain,
Independent Director -
James Tyree,
Independent Director -
Henry McKinnell,
Independent Director -
Thomas Edwards,
Independent Director -
Joseph Feczko,
Independent Director -
Geoffrey Parker,
Independent Director -
Dr. Rita I. Jain M.D.,
Exec. VP, Chief Medical Officer & Exec. Employee Director -
Dr. Sangita Ghosh Ph.D.,
Sr. VP of Technical Operations -
Dalia R. Rayes,
Sr. VP & Head of Commercial -
Kari E. Leetch,
Sr. VP of HR -
Tausif Butt,
Exec. VP & COO -
Roger C Lucas,
Director -
Petrus Bekker,
SVP of Medical & Clinical -
Rajinder Singh,
SVP, Research -
Partners L P/Ilbiotechnolog...,
-
Jennifer Lyn Herron,
Director -
Pui San Kwan,
Principal Acctg Officer -
William Fairey,
Chief Operating Officer -
Plc Gsk,
10% owner -
Edward Penhoet,
Director -
Ira Klein,
Director -
Partners L P/Ilbiotechnolog...,
-
Anne Marie Duliege,
EVP, Chief of Strategic Dev. -
Israel Charo,
SVP, Research -
Juan C. Jaen,
SVP, Drug Discovery & CSO -
Tausif Butt,
EVP, Chief Operating Officer -
Partners L P/Ilbvf Investme...,
-
Corp /Mn/ Techne,
10% owner -
Advisors Llcorbimed Capital...,
-
Rishi Gupta,
Director -
(International) Ltd Vifor P...,
-
Yi Ching Yau,
SVP, Finance & Acctg Officer -
David E. Wheadon,
Director